PB09
Nov 21, 8:53 AM
Here is some Hopium
$CAPR — still see a possible path here.
* HOPE-3 published in The Lancet
* Trial doctors publicly backed approval
* Patient/family testimony at AdCom
* Eliquis (
$BMY/
$PFE), Ryoncil (
$MESO), Vyondys 53 (
$SRPT): CRLs → eventual approvals
FDA says HOPE-3’s data issues can’t be fixed after the fact. Serious hurdle.
Tell them What actually happened, using original records.
The scope and timing of any loss of blinding.
Who had access to treatment information when analytical changes were made.
Whether an acceptable analysis of reliable data still supports efficacy.
Whether FDA agrees that the problems have been adequately bounded.
Still believe eventual approval is possible if CAPR can establish a path FDA will accept.
1 replies